| Literature DB >> 32488569 |
Zi-Wen Han1,2, Zhi-Wu Lyv3, Bin Cui3, Ying-Ying Wang1,2, Jun-Ting Cheng1,2, Ying Zhang1,2, Wen-Qi Cai1,2, Yang Zhou1,2, Zhao-Wu Ma1,2, Xian-Wang Wang1,2,4, Xiao-Chun Peng1,2,5, Shu-Zhong Cui6, Ying Xiang7,8, Mo Yang9, Hong-Wu Xin10,11.
Abstract
Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) contain 12 family members(CEACAM1、CEACAM3、CEACAM4、CEACAM5、CEACAM6、CEACAM7、CEACAM8、CEACAM16、CEACAM18、CEACAM19、CEACAM20 and CEACAM21)and are expressed diversely in different normal and tumor tissues. CEA (CEACAM5) has been used as a tumor biomarker since 1965. Here we review the latest research and development of the structures, expression, and function of CEACAMs in normal and tumor tissues, and their application in the tumor diagnosis, prognosis, and treatment. We focus on recent clinical studies of CEA targeted cancer immunotherapies, including bispecific antibody (BsAb) for radio-immuno-therapy and imaging, bispecific T cell engager (BiTE) and chimeric antigen receptor T cells (CAR-T). We summarize the promising clinical relevance and challenges of these approaches and give perspective view for future research. This review has important implications in understanding the diversified biology of CEACAMs in normal and tumor tissues, and their new role in tumor immunotherapy.Entities:
Keywords: Bispecific Antibody (BsAb); Bispecific T cell engager (BiTE); Carcinoembryonic Antigen-related Cell Adhesion Molecules (CEACAMs); Chimeric Antigen Receptor T cell (CAR-T); Tumor immunotherapy
Year: 2020 PMID： 32488569 DOI： 10.1007/s10637-020-00955-w
Source DB: PubMed Journal: Invest New Drugs ISSN： 0167-6997 Impact factor: 3.850